<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> (<z:chebi fb="0" ids="48432">AngII</z:chebi>) mediates progression of <z:hpo ids='HP_0004942'>aortic aneurysm</z:hpo>, but the relative contribution of its type 1 (AT1) and type 2 (AT2) receptors remains unknown </plain></SENT>
<SENT sid="1" pm="."><plain>We show that loss of AT2 expression accelerates the aberrant growth and rupture of the aorta in a mouse model of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>The selective AT1 receptor blocker (ARB) <z:chebi fb="0" ids="6541">losartan</z:chebi> abrogated <z:hpo ids='HP_0002617'>aneurysm</z:hpo> progression in the mice; full protection required intact AT2 signaling </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi> (ACEi) enalapril, which limits signaling through both receptors, was less effective </plain></SENT>
<SENT sid="4" pm="."><plain>Both drugs attenuated canonical transforming growth factor-β (TGFβ) signaling in the aorta, but <z:chebi fb="0" ids="6541">losartan</z:chebi> uniquely inhibited TGFβ-mediated activation of extracellular signal-regulated kinase (ERK), by allowing continued signaling through AT2 </plain></SENT>
<SENT sid="5" pm="."><plain>These data highlight the protective nature of AT2 signaling and potentially inform the choice of therapies in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and related disorders </plain></SENT>
</text></document>